دورية أكاديمية
Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Biological Carriers for Drug Delivery in Cancer Therapy.
| العنوان: | Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Biological Carriers for Drug Delivery in Cancer Therapy. |
|---|---|
| المؤلفون: | Sanmartin MC; Laboratorio de Inmunohematología, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.; Laboratorio de Regulación Génica y Células Madre, Instituto de Medicina Traslacional, Trasplante y Bioingeniería (IMeTTyB), Universidad Favaloro - CONICET, Buenos Aires, Argentina., Borzone FR; Laboratorio de Inmunohematología, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina., Giorello MB; Laboratorio de Inmunohematología, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina., Yannarelli G; Laboratorio de Regulación Génica y Células Madre, Instituto de Medicina Traslacional, Trasplante y Bioingeniería (IMeTTyB), Universidad Favaloro - CONICET, Buenos Aires, Argentina., Chasseing NA; Laboratorio de Inmunohematología, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina. |
| المصدر: | Frontiers in bioengineering and biotechnology [Front Bioeng Biotechnol] 2022 Apr 14; Vol. 10, pp. 882545. Date of Electronic Publication: 2022 Apr 14 (Print Publication: 2022). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101632513 Publication Model: eCollection Cited Medium: Print ISSN: 2296-4185 (Print) Linking ISSN: 22964185 NLM ISO Abbreviation: Front Bioeng Biotechnol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Media S.A., [2013]- |
| مستخلص: | Cancer is the second leading cause of death worldwide, with 10.0 million cancer deaths in 2020. Despite advances in targeted therapies, some pharmacological drawbacks associated with anticancer chemo and immunotherapeutic agents include high toxicities, low bioavailability, and drug resistance. In recent years, extracellular vesicles emerged as a new promising platform for drug delivery, with the advantage of their inherent biocompatibility and specific targeting compared to artificial nanocarriers, such as liposomes. Particularly, mesenchymal stem/stromal cells were proposed as a source of extracellular vesicles for cancer therapy because of their intrinsic properties: high in vitro self-renewal and proliferation, regenerative and immunomodulatory capacities, and secretion of extracellular vesicles that mediate most of their paracrine functions. Moreover, extracellular vesicles are static and safer in comparison with mesenchymal stem/stromal cells, which can undergo genetic/epigenetic or phenotypic changes after their administration to patients. In this review, we summarize currently reported information regarding mesenchymal stem/stromal cell-derived extracellular vesicles, their proper isolation and purification techniques - from either naive or engineered mesenchymal stem/stromal cells - for their application in cancer therapy, as well as available downstream modification methods to improve their therapeutic properties. Additionally, we discuss the challenges associated with extracellular vesicles for cancer therapy, and we review some preclinical and clinical data available in the literature. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Sanmartin, Borzone, Giorello, Yannarelli and Chasseing.) |
| References: | Stem Cells. 2006 May;24(5):1294-301. (PMID: 16410387) J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Apr 15;1169:122604. (PMID: 33713953) J Neuroimmune Pharmacol. 2020 Sep;15(3):459-472. (PMID: 31512168) Biosci Rep. 2019 May 3;39(5):. (PMID: 30979829) Oncotarget. 2017 Aug 14;8(42):73296-73311. (PMID: 29069870) Mol Cancer. 2018 Aug 15;17(1):122. (PMID: 30111323) ACS Appl Mater Interfaces. 2021 Dec 1;13(47):55767-55779. (PMID: 34793116) J Extracell Vesicles. 2018 Dec 28;8(1):1560809. (PMID: 30651940) Exp Cell Res. 2020 Sep 15;394(2):112144. (PMID: 32540398) Tissue Eng Part B Rev. 2020 Apr;26(2):129-144. (PMID: 31847715) Adv Healthc Mater. 2022 Mar;11(5):e2100639. (PMID: 34165909) Front Cell Neurosci. 2017 Oct 13;11:312. (PMID: 29081734) Stem Cell Res Ther. 2017 Apr 27;8(1):103. (PMID: 28449711) J Extracell Vesicles. 2015 Feb 09;4:26238. (PMID: 25669322) Acta Pharm Sin B. 2020 Aug;10(8):1563-1575. (PMID: 32963950) Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Jun;17(3):695-9. (PMID: 19549390) Exp Mol Med. 2013 Jan 10;45:e2. (PMID: 23306700) Sultan Qaboos Univ Med J. 2018 Aug;18(3):e264-e277. (PMID: 30607265) Front Pharmacol. 2018 Feb 28;9:169. (PMID: 29541030) Cell Death Dis. 2020 May 11;11(5):349. (PMID: 32393744) Stem Cell Res Ther. 2018 Mar 22;9(1):75. (PMID: 29566772) Aging (Albany NY). 2019 Aug 5;11(15):5300-5318. (PMID: 31386624) Leukemia. 2018 Jul;32(7):1500-1514. (PMID: 29535427) Stem Cells Int. 2019 Mar 6;2019:7012692. (PMID: 30956673) Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230) Pharmacol Res. 2020 Jul;157:104843. (PMID: 32360582) Cell Prolif. 2020 Jan;53(1):e12712. (PMID: 31730279) Cell Commun Signal. 2021 Oct 16;19(1):104. (PMID: 34656117) Drug Deliv. 2022 Dec;29(1):192-202. (PMID: 34984953) J Extracell Vesicles. 2021 Feb;10(4):e12057. (PMID: 33643546) Acta Pharmacol Sin. 2018 Apr;39(4):542-551. (PMID: 29417947) Stem Cell Res Ther. 2017 Oct 27;8(1):238. (PMID: 29078809) Stem Cell Rev Rep. 2019 Jun;15(3):356-373. (PMID: 30937640) J Extracell Vesicles. 2019 Apr 29;8(1):1609206. (PMID: 31069028) Aging (Albany NY). 2021 Feb 1;13(4):5055-5068. (PMID: 33535172) Int J Pharm. 2018 Oct 5;549(1-2):218-229. (PMID: 30075248) Cells. 2019 Jul 28;8(8):. (PMID: 31357692) Blood. 2007 Nov 15;110(10):3499-506. (PMID: 17664353) Bioconjug Chem. 2021 Apr 21;32(4):680-684. (PMID: 33719402) Stem Cell Res Ther. 2016 Apr 16;7(1):55. (PMID: 27084088) Cells. 2020 Mar 13;9(3):. (PMID: 32183102) J Extracell Vesicles. 2019 Jun 17;8(1):1626654. (PMID: 31258880) Methods. 2020 May 1;177:95-102. (PMID: 31568822) Cancer Sci. 2010 Dec;101(12):2546-53. (PMID: 20942864) Drug Deliv. 2021 Dec;28(1):162-170. (PMID: 33427518) Stem Cells Transl Med. 2018 Jul;7(7):543-550. (PMID: 29665255) J Cell Physiol. 2020 Apr;235(4):3698-3710. (PMID: 31566731) Front Immunol. 2018 May 23;9:1111. (PMID: 29875772) Biomaterials. 2021 Aug;275:121000. (PMID: 34218049) J Exp Clin Cancer Res. 2020 Jan 2;39(1):4. (PMID: 31898515) Eur J Pharm Biopharm. 2019 Nov;144:50-56. (PMID: 31419585) Pharmaceutics. 2020 May 11;12(5):. (PMID: 32403320) Cancer Sci. 2017 Oct;108(10):1939-1946. (PMID: 28756624) J Control Release. 2016 Feb 28;224:77-85. (PMID: 26773767) J Hematol Oncol. 2012 Apr 30;5:19. (PMID: 22546280) Nat Rev Clin Oncol. 2020 Apr;17(4):251-266. (PMID: 32034288) Clin Exp Metastasis. 2013 Mar;30(3):317-32. (PMID: 23053744) Methods Mol Biol. 2017;1660:409-432. (PMID: 28828676) Carbohydr Polym. 2018 Dec 15;202:323-333. (PMID: 30287007) Stem Cell Investig. 2019 Sep 25;6:34. (PMID: 31620481) Methods. 2020 May 1;177:114-125. (PMID: 31790730) Adv Drug Deliv Rev. 2021 Aug;175:113836. (PMID: 34166759) Sci Rep. 2017 Oct 31;7(1):14444. (PMID: 29089562) J Cell Biochem. 2012 May;113(5):1460-9. (PMID: 22213121) J Nanobiotechnology. 2021 Oct 30;19(1):354. (PMID: 34717658) J Nanobiotechnology. 2018 Aug 30;16(1):61. (PMID: 30165851) Front Mol Biosci. 2021 Jun 18;8:680580. (PMID: 34222335) Int J Mol Sci. 2021 Jan 15;22(2):. (PMID: 33467725) Stem Cells Transl Med. 2017 Aug;6(8):1730-1739. (PMID: 28714557) Stem Cell Res Ther. 2020 Feb 26;11(1):87. (PMID: 32102682) Cells. 2018 Dec 16;7(12):. (PMID: 30558352) Front Bioeng Biotechnol. 2020 Feb 05;8:43. (PMID: 32117924) Trends Biotechnol. 2019 Jul;37(7):707-729. (PMID: 30638682) BMC Cancer. 2018 Oct 19;18(1):999. (PMID: 30340558) Pharmacol Res. 2022 Jan;175:105980. (PMID: 34863822) Trends Pharmacol Sci. 2021 Nov;42(11):883-896. (PMID: 34598797) PLoS One. 2020 Jan 30;15(1):e0227949. (PMID: 31999742) Front Cell Dev Biol. 2021 Mar 01;9:629893. (PMID: 33732698) Cell Mol Life Sci. 2021 Jan;78(2):447-467. (PMID: 32699947) Acta Biomater. 2019 Mar 1;86:1-14. (PMID: 30597259) Int J Cancer. 2021 Apr 5;:. (PMID: 33818764) Artif Intell Med. 2020 Mar;103:101789. (PMID: 32143796) Burns. 2022 Dec;48(8):1893-1908. (PMID: 35016791) ACS Cent Sci. 2022 Jan 26;8(1):110-117. (PMID: 35111901) Cancer Med. 2019 Dec;8(18):7728-7740. (PMID: 31642612) Stem Cells. 2020 May;38(5):698-711. (PMID: 32064745) Philos Trans R Soc Lond B Biol Sci. 2018 Jan 5;373(1737):. (PMID: 29158309) Adv Exp Med Biol. 2021;1312:107-129. (PMID: 33159306) Adv Drug Deliv Rev. 2021 Jul;174:535-552. (PMID: 33991589) Neuro Oncol. 2018 Feb 19;20(3):380-390. (PMID: 29016843) J Vis Exp. 2021 Mar 28;(169):. (PMID: 33843938) Nature. 2017 Jun 22;546(7659):498-503. (PMID: 28607485) J Biol Eng. 2019 Jan 18;13:7. (PMID: 30675180) ACS Nano. 2018 Jul 24;12(7):6830-6842. (PMID: 29975503) J Tissue Eng Regen Med. 2019 Sep;13(9):1738-1755. (PMID: 31216380) Cancer Metastasis Rev. 2019 Jun;38(1-2):93-101. (PMID: 30715644) Adv Mater. 2021 Apr;33(14):e2005709. (PMID: 33644908) Front Physiol. 2019 Mar 19;10:226. (PMID: 30941051) Mol Oncol. 2018 May;12(5):659-676. (PMID: 29517849) Life Sci. 2022 Jan 15;289:120210. (PMID: 34875250) Stem Cells Int. 2019 Mar 14;2019:8108576. (PMID: 31001342) Biotechnol Bioeng. 2020 Aug;117(8):2588-2609. (PMID: 32333387) CA Cancer J Clin. 2020 Mar;70(2):105-124. (PMID: 32068901) Int J Pharm. 2021 May 1;600:120477. (PMID: 33737099) Tissue Eng Regen Med. 2018 Jul 12;15(4):427-436. (PMID: 30603566) J Extracell Vesicles. 2020 Aug 19;9(1):1806444. (PMID: 32944191) J Extracell Vesicles. 2021 Jun;10(8):e12085. (PMID: 34194679) Acc Chem Res. 2019 Jul 16;52(7):1761-1770. (PMID: 31181910) Cancers (Basel). 2020 Jan 27;12(2):. (PMID: 32012717) Stem Cells. 2013 Jan;31(1):215-20. (PMID: 23097343) Mol Cancer Res. 2010 Aug;8(8):1074-83. (PMID: 20663859) Nat Rev Mol Cell Biol. 2011 Feb;12(2):126-31. (PMID: 21253000) J Biomed Sci. 2018 Mar 30;25(1):31. (PMID: 29602309) Stem Cells Int. 2012;2012:652034. (PMID: 22685475) Adv Drug Deliv Rev. 2021 Jun;173:252-278. (PMID: 33798644) Biomedicines. 2021 Jun 10;9(6):. (PMID: 34200818) Oncotarget. 2021 May 25;12(11):1029-1031. (PMID: 34084276) Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228. (PMID: 29339798) Daru. 2020 Jun;28(1):295-304. (PMID: 30666557) Nature. 2014 Nov 6;515(7525):130-3. (PMID: 25337873) Cytotherapy. 2006;8(4):315-7. (PMID: 16923606) J Hematol Oncol. 2021 Sep 3;14(1):136. (PMID: 34479611) Biochim Biophys Acta. 2012 Jul;1820(7):940-8. (PMID: 22503788) Int Immunopharmacol. 2021 Aug;97:107694. (PMID: 33932694) Eur Neurol. 2020;83(3):235-241. (PMID: 32690856) Autophagy. 2020 Dec;16(12):2140-2155. (PMID: 31959090) ACS Sens. 2019 May 24;4(5):1245-1251. (PMID: 30915846) Cytometry A. 2018 Jan;93(1):19-31. (PMID: 29072818) J Extracell Vesicles. 2020 Nov;10(1):e12033. (PMID: 33708360) Nanoscale. 2019 Jan 23;11(4):1531-1537. (PMID: 30623961) Stem Cell Rev Rep. 2020 Jun;16(3):541-556. (PMID: 31898802) Neuro Oncol. 2010 May;12(5):453-65. (PMID: 20406896) Basic Clin Pharmacol Toxicol. 2004 Nov;95(5):209-14. (PMID: 15546474) Leukemia. 2009 May;23(5):925-33. (PMID: 19148141) Front Immunol. 2014 Aug 11;5:382. (PMID: 25157253) J Bone Miner Res. 2009 Mar;24(3):425-36. (PMID: 19016584) J Exp Clin Cancer Res. 2020 Jul 22;39(1):140. (PMID: 32698859) Nat Commun. 2016 Jul 22;7:12277. (PMID: 27447450) Cell Stem Cell. 2009 Jul 2;5(1):54-63. (PMID: 19570514) Adv Drug Deliv Rev. 2021 Oct;177:113940. (PMID: 34419502) Front Immunol. 2018 Jun 13;9:1326. (PMID: 29951064) PLoS One. 2014 Nov 24;9(11):e113572. (PMID: 25419563) ACS Nano. 2020 Apr 28;14(4):4444-4455. (PMID: 32282185) iScience. 2019 Jun 28;16:230-241. (PMID: 31195240) J Nanobiotechnology. 2019 Jul 18;17(1):85. (PMID: 31319859) Exp Cell Res. 2005 Jun 10;306(2):330-5. (PMID: 15925588) Cancer Cell. 2020 Dec 14;38(6):788-802. (PMID: 32946773) J Extracell Vesicles. 2020 Sep 4;9(1):1809766. (PMID: 33144926) Front Immunol. 2021 Jun 03;12:684496. (PMID: 34149726) Int Immunopharmacol. 2020 Feb;79:106172. (PMID: 31926480) Cell Death Discov. 2021 Aug 28;7(1):224. (PMID: 34455417) J Mammary Gland Biol Neoplasia. 2021 Jun;26(2):135-155. (PMID: 33398516) Cells. 2020 May 08;9(5):. (PMID: 32397238) Methods Mol Biol. 2017;1660:25-32. (PMID: 28828645) Nat Nanotechnol. 2021 Jul;16(7):748-759. (PMID: 34211166) Stem Cells Dev. 2010 Mar;19(3):359-70. (PMID: 19388812) Cell Biosci. 2020 May 24;10:69. (PMID: 32483483) J Transl Med. 2013 Apr 10;11:94. (PMID: 23574623) Stem Cells Int. 2018 Sep 12;2018:9415367. (PMID: 30275839) Nanoscale. 2019 Nov 21;11(43):20884-20892. (PMID: 31660556) Stem Cells. 2008 Jan;26(1):99-107. (PMID: 17916800) Front Pharmacol. 2018 Mar 20;9:259. (PMID: 29615915) Expert Opin Ther Targets. 2011 Jul;15(7):817-28. (PMID: 21391891) Adv Healthc Mater. 2022 Mar;11(5):e2100538. (PMID: 34310074) Adv Drug Deliv Rev. 2021 Nov;178:113961. (PMID: 34481030) Cytotherapy. 2021 May;23(5):373-380. (PMID: 33934807) Biomed Pharmacother. 2020 Aug;128:110237. (PMID: 32470747) BMB Rep. 2018 Aug;51(8):406-411. (PMID: 29966581) Cells. 2020 Sep 29;9(10):. (PMID: 33003285) Cancer Biol Ther. 2008 Feb;7(2):245-51. (PMID: 18059192) Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2481-2491. (PMID: 31219352) Nanomedicine (Lond). 2019 Nov;14(21):2799-2814. (PMID: 31724479) Med Drug Discov. 2020 Mar;5:100019. (PMID: 32296777) Biomolecules. 2019 Dec 28;10(1):. (PMID: 31905611) Pharmaceutics. 2019 Oct 28;11(11):. (PMID: 31661862) Nat Med. 1999 Mar;5(3):309-13. (PMID: 10086387) Cytotherapy. 2019 Jun;21(6):581-592. (PMID: 30979664) Cells. 2020 Aug 25;9(9):. (PMID: 32854228) Tissue Eng Regen Med. 2020 Aug;17(4):537-552. (PMID: 32506351) J Cell Physiol. 2020 Nov;235(11):7663-7680. (PMID: 32324279) Biology (Basel). 2020 Jan 20;9(1):. (PMID: 31968627) Cell Biol Toxicol. 2020 Apr;36(2):165-178. (PMID: 31820164) Adv Drug Deliv Rev. 2021 Jun;173:416-426. (PMID: 33831479) Int J Nanomedicine. 2019 Nov 01;14:8603-8610. (PMID: 31802872) Future Med Chem. 2019 May;11(10):1225-1236. (PMID: 31280675) Front Bioeng Biotechnol. 2020 Aug 31;8:1010. (PMID: 32984284) J Nanobiotechnology. 2018 Dec 20;16(1):103. (PMID: 30572882) J Extracell Vesicles. 2020 Jan 7;9(1):1710020. (PMID: 32002172) Stem Cells Transl Med. 2017 Dec;6(12):2173-2185. (PMID: 29076267) Front Bioeng Biotechnol. 2020 Sep 10;8:997. (PMID: 33015001) ACS Nano. 2020 Aug 25;14(8):9728-9743. (PMID: 32697573) J Cell Mol Med. 2021 Feb;25(4):1911-1926. (PMID: 33350586) Crit Rev Oncol Hematol. 2021 Aug;164:103416. (PMID: 34237436) Stem Cells Transl Med. 2020 Sep;9(9):985-1006. (PMID: 32497410) Exp Mol Med. 2020 Jan;52(1):1-6. (PMID: 31915368) ACS Biomater Sci Eng. 2021 Dec 13;7(12):5823-5835. (PMID: 34846835) Bioconjug Chem. 2019 Aug 21;30(8):2150-2155. (PMID: 31322343) Tissue Cell. 2020 Jun;64:101330. (PMID: 32473704) Oncol Rep. 2019 Apr;41(4):2126-2136. (PMID: 30816504) Int J Nanomedicine. 2019 Nov 12;14:8847-8859. (PMID: 32009783) J Lipid Res. 2018 Nov;59(11):2037-2046. (PMID: 29678959) Blood. 2004 Jun 15;103(12):4619-21. (PMID: 15001472) Int J Mol Med. 2014 Sep;34(3):695-704. (PMID: 24970492) J Extracell Vesicles. 2019 Aug 1;8(1):1648167. (PMID: 31489144) Int J Cancer. 2019 Feb 15;144(4):897-908. (PMID: 30098225) Biology (Basel). 2021 Feb 10;10(2):. (PMID: 33579033) Cells. 2022 Jan 06;11(2):. (PMID: 35053301) Mol Ther. 2013 Jan;21(1):185-91. (PMID: 23032975) Int J Mol Sci. 2020 Mar 05;21(5):. (PMID: 32151085) Cancer Lett. 2013 Jul 10;335(1):201-4. (PMID: 23419525) J Extracell Vesicles. 2021 Jan;10(3):e12061. (PMID: 33532042) Life Sci. 2020 Nov 15;261:118369. (PMID: 32882265) J Transl Med. 2020 Jan 30;18(1):42. (PMID: 32000804) Mol Ther. 2021 May 5;29(5):1729-1743. (PMID: 33484965) Front Pharmacol. 2018 Sep 26;9:1116. (PMID: 30319428) Front Immunol. 2016 Jan 06;6:648. (PMID: 26779185) Int J Mol Sci. 2020 May 01;21(9):. (PMID: 32370075) Cancers (Basel). 2019 Dec 09;11(12):. (PMID: 31835327) |
| فهرسة مساهمة: | Keywords: cancer therapy; cell-free therapy; drug delivery systems; extracellular vesicles; mesenchymal stem/ stromal cells |
| تواريخ الأحداث: | Date Created: 20220502 Latest Revision: 20231101 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC9046597 |
| DOI: | 10.3389/fbioe.2022.882545 |
| PMID: | 35497332 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2296-4185 |
|---|---|
| DOI: | 10.3389/fbioe.2022.882545 |